Teva gets final approval for generic DuoNeb

JERUSALEM The Food and Drug Administration has granted final approval to Teva Pharmaceuticals for its application for a generic version of Dey’s drug DuoNeb.

DuoNeb is a bronchodilator that increases airflow by dilating the bronchi and bronchioles. The generic, albuterol sulfate and ipratropium bromide inhalation solution will be available in 3 mg (0.083 percent) and 0.5 mg (0.017 percent).

The brand product had annual sales of approximately $265 million in the United States for the twelve months ended Sept. 30, 2007, based on IMS sales data. The company will begin shipping the product immediately.

Login or Register to post a comment.